The paper is devoted to the problem of clinical efficacy and pharmacoeconomic evaluation of Spiolto Respimat. The results of clinical trials prove that Spiolto Respimat in patients with COPD improves spirometric values, symptoms of dyspnea and health-related quality of life, compared with placebo, tiotropium bromide (5 μg) and olodaterol (5 μg). According to conducted in European countries pharmacoeconomic analysis «cost-utility» therapy with Spiolto Respimat results in quality-adjusted life-year gained comparing to tiotropium bromide (5 μg). Also Spiolto Respimat is an effective option of COPD therapy comparing to the other combinations of long-acting muscarinic antagonist – long-acting beta2-adrenergic agonist.